Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 4/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13204445 | 1.00 | ACACB (0.42) | ACACBENPP3ENPP1ENPP2KMT2A | |
| SCHEMBL13204264 | 0.94 | HRH3 (0.44) | ACACBENPP3ENPP1ENPP2KMT2A | |
| SCHEMBL10114664 | 0.94 | HRH3 (0.44) | ACACBENPP3ENPP1ENPP2KMT2A | |
| SCHEMBL10114618 | 0.86 | ENPP3 (0.51) | ACACBENPP3ENPP1ENPP2STS | |
| SCHEMBL14424355 | 0.86 | ENPP3 (0.51) | ACACBENPP3ENPP1ENPP2STS | |
| SCHEMBL10114590 | 0.86 | NPY5R (0.46) | ACACBENPP3ENPP1ENPP2KMT2A | |
| SCHEMBL14424356 | 0.86 | NPY5R (0.46) | ACACBENPP3ENPP1ENPP2KMT2A | |
| SCHEMBL10114920 | 0.85 | ENPP3 (0.53) | ENPP3ENPP1ENPP2STSNPSR1 | |
| SCHEMBL14424383 | 0.85 | ENPP3 (0.53) | ENPP3ENPP1ENPP2STSNPSR1 | |
| SCHEMBL10116152 | 0.84 | NAMPT (0.49) | ACACBRAB9ANAMPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | ACACB 3070/4885ENPP3 3225/4885ENPP1 3059/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | ACACB 3095/4885ENPP3 3416/4885ENPP1 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.